首页|沙库巴曲缬沙坦治疗老年慢性重度心力衰竭患者的临床效果及对心功能的影响

沙库巴曲缬沙坦治疗老年慢性重度心力衰竭患者的临床效果及对心功能的影响

扫码查看
目的 研究沙库巴曲缬沙坦治疗老年慢性重度心力衰竭患者的临床效果及对心功能的影响.方法 选取2022年1月至12月收治的100例老年慢性重度心力衰竭患者为研究对象,按照治疗方式不同将其分为对照组(48例)和研究组(52例).对照组接受常规药物治疗,研究组在对照组基础上联用沙库巴曲缬沙坦治疗.比较两组的临床疗效、心功能指标、心肌损伤指标、神经内分泌指标及生活质量.结果 研究组的治疗总有效率高于对照组(P<0.05).治疗后,研究组的左心室射血分数(LVEF)大于对照组,左心室质量指数(LVMI)、左心室舒张末期内径(LVEDD)小于对照组(P<0.05).治疗后,研究组的肌酸激酶同工酶(CK-MB)、心肌肌钙蛋白Ⅰ(cTnⅠ)及N末端脑钠肽前体(NT-proBNP)水平低于对照组(P<0.05).治疗后,研究组的醛固酮(ALD)、血管紧张素Ⅱ(AngⅡ)及去甲肾上腺素(NE)水平低于对照组(P<0.05).治疗后,研究组的情绪、躯体及其他评分低于对照组(P<0.05).结论 沙库巴曲缬沙坦治疗老年慢性重度心力衰竭患者的临床效果确切,可明显改善患者的心功能,延缓心力衰竭进展,提升生活质量.
Clinical effect of sacubitril valsartan in the treatment of elderly patients with chronic severe heart failure and its influence on cardiac function
Objective To study the clinical effect of sacubitril valsartan in the treatment of elderly patients with chronic severe heart failure and its influence on cardiac function.Methods A total of 100 elderly patients with chronic severe heart failure admitted from January to December 2022 were selected as the research objects.According to different treatment methods,the patients were divided into control group(48 cases)and study group(52 cases).The control group received conventional drug treatment,and the study group was treated with sacubitril valsartan on the basis of the control group.The clinical efficacy,cardiac function indexes,myocardial injury indexes,neuroendocrine indexes and quality of life were compared between the two groups.Results The total effective rate of treatment in the study group was higher than that in the control group(P<0.05).After treatment,the left ventricular ejection fraction(LVEF)in the study group was greater than that in the control group,and the left ventricular mass index(LVMI)and left ventricular end-diastolic diameter(LVEDD)were smaller than those in the control group(P<0.05).After treatment,the levels of creatine kinase isoenzymes-MB(CK-MB),cardiac troponin Ⅰ(cTnⅠ)and N-terminal pro-brain natriuretic peptide(NT-proBNP)in the study group were lower than those in the control group(P<0.05).After treatment,the levels of aldosterone(ALD),angiotensin Ⅱ(Ang Ⅱ)and norepinephrine(NE)in the study group were lower than those in the control group(P<0.05).After treatment,the scores of emotion,body and others in the study group were lower than those in the control group(P<0.05).Conclusion The sacubitril valsartan in the treatment of elderly patients with chronic severe heart failure has definite clinical effect,which can significantly improve the cardiac function of patients,delay the progression of heart failure and promote the quality of life.

heart failuresacubitril valsartancardiac troponin ⅠN-terminal pro-brain natriuretic peptide

田静、刘小芬、杨伟

展开 >

陕西省合阳县中医医院,陕西渭南,715300

西安交通大学第一附属医院,陕西西安,710061

心力衰竭 沙库巴曲缬沙坦 心肌肌钙蛋白Ⅰ N末端脑钠肽前体

2024

临床医学研究与实践

临床医学研究与实践

ISSN:
年,卷(期):2024.9(36)
  • 1